The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

• Status: Not yet recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether adding sulodexide to the patients with varicose veins who received radiofrequency ablation combined with sclerotherapy can reduce or improve the impact of adverse events。

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chengdu University of Traditional Chinese Medicine
• Treatments: Glucuronyl glucosamine glycan sulfate

Criteria

Inclusion Criteria:

• Age >18 years and <80 years, and able to understand the requirements of the study and provide informed consent and accept the exams and follow-up.

• C2 - C5 varicose veins / CVI Symptomatic primary GSV, SSV, or AASV incompetence, with reflux >0.5 seconds on color duplex, eligible for patients undergoing radiofrequency ablation plus sclerotherapy

• BMI<35

• The skin color is within the normal range, and no obvious skin color unevenness or skin diseases affect the observed indicators.

Exclusion Criteria:

• Acute superficial or deep vein thrombosis

• History of asthma and stroke

• There are skin diseases, scars, infections, and other conditions in the surgical area that affect the observation indicators

• Pregnancy

• Serious damage to liver and kidney function

• Severe obesity (BMI>35) and severe edema of the lower extremities

• Others are not eligible for intravenous radiofrequency ablation combined with sclerotherapy